Meredith Cook Sells 250 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $67.79, for a total value of $16,947.50. Following the completion of the transaction, the vice president now directly owns 59,731 shares in the company, valued at $4,049,164.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Tuesday, February 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $56.04, for a total value of $14,010.00.

ANI Pharmaceuticals Trading Down 1.1 %

NASDAQ ANIP opened at $65.56 on Wednesday. The company has a market cap of $1.38 billion, a price-to-earnings ratio of 78.05 and a beta of 0.79. ANI Pharmaceuticals, Inc. has a 52 week low of $36.99 and a 52 week high of $70.81. The business has a 50 day moving average price of $64.41 and a 200-day moving average price of $58.47. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $131.65 million during the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ANIP. Swiss National Bank increased its holdings in shares of ANI Pharmaceuticals by 7.1% during the first quarter. Swiss National Bank now owns 27,000 shares of the specialty pharmaceutical company’s stock valued at $759,000 after acquiring an additional 1,800 shares in the last quarter. Citigroup Inc. increased its holdings in shares of ANI Pharmaceuticals by 44.9% during the first quarter. Citigroup Inc. now owns 12,516 shares of the specialty pharmaceutical company’s stock valued at $352,000 after acquiring an additional 3,881 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of ANI Pharmaceuticals by 15.4% during the first quarter. PNC Financial Services Group Inc. now owns 3,828 shares of the specialty pharmaceutical company’s stock valued at $108,000 after acquiring an additional 512 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of ANI Pharmaceuticals by 57.0% during the first quarter. MetLife Investment Management LLC now owns 5,858 shares of the specialty pharmaceutical company’s stock valued at $165,000 after acquiring an additional 2,127 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of ANI Pharmaceuticals by 4.4% during the first quarter. Rhumbline Advisers now owns 25,916 shares of the specialty pharmaceutical company’s stock valued at $728,000 after acquiring an additional 1,096 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of recent analyst reports. Capital One Financial initiated coverage on ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective on the stock. HC Wainwright boosted their price target on ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Guggenheim boosted their price target on ANI Pharmaceuticals from $70.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Finally, Truist Financial boosted their price target on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $80.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.